Summary of published data on SPMs in MM patients
| Study (median follow-up) . | Treatment schedule . | Overall SPMs . | % SPMs . |
|---|---|---|---|
| IFM 2005-027 (24 mo) | R | 17/299 | 5.5% |
| Placebo | 3/292 | 1% | |
| CALGB 1001048 (28 mo) | R | 15/231 | 6.5% |
| Placebo | 6/229 | 2.6% | |
| MM-015 9 (30 mo) | MPR-R/MPR | 11/335 | 3.1% |
| Placebo | 2/154 | 1.3% |
| Study (median follow-up) . | Treatment schedule . | Overall SPMs . | % SPMs . |
|---|---|---|---|
| IFM 2005-027 (24 mo) | R | 17/299 | 5.5% |
| Placebo | 3/292 | 1% | |
| CALGB 1001048 (28 mo) | R | 15/231 | 6.5% |
| Placebo | 6/229 | 2.6% | |
| MM-015 9 (30 mo) | MPR-R/MPR | 11/335 | 3.1% |
| Placebo | 2/154 | 1.3% |
M indicates melphalan; and P, prednisone.